TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction April 28, 2006